Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Aparicio, Jorge; Virgili Manrique, Anna C; Capdevila, Jaume; Muñoz Boza, Félix; Galván, Patricia; Richart, Paula; Oliveres, Helena; Páez, David; Hernando, Jorge; Serrano, Sara; Vera, Ruth.
Clin. transl. oncol. (Print) ; 24(11): 2155-2165, noviembre 2022. graf, tab
Artículo en Inglés | IBECS (España) | ID: ibc-210143

Documentos relacionados

  1. [FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer].
  2. [Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital].
  3. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer.
  4. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
  5. Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
  6. [FOLFIRI plus Ramucirumab Treatment for Metastatic Colorectal Cancer-Narrative Review of Real-World Evidence in Japan].
  7. A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer.
  8. Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
  9. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
  10. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.